In a mouse model of allergic asthma, exogenous Semaphorin 3E (Sema3E) treatment reduces Th17 cytokine response leading to diminished collagen deposition, airway hyperresponsiveness, and eosinophilic inflammation [87]. This evidence concerns the gene SEMA3E and allergic asthma.